106 filings
Page 5 of 6
6-K
qbnvc 73lebpqux3y
12 Nov 19
Aslan Pharmaceuticals Announces Topline Results from Treetopp Global Pivotal Study of Varlitinib In Biliary Tract Cancer
6:03am
6-K
st6 m5s9uvucjj34o7r
5 Nov 19
Current report (foreign)
6:04am
6-K
crnl 9n17jj
31 Oct 19
Current report (foreign)
7:15am
6-K
8wju0c6
23 Oct 19
Current report (foreign)
6:07am
6-K
itfgros
18 Oct 19
Aslan Pharmaceuticals Announces Closing of US$3 Million Loan Facility
8:56am
6-K
qw2bl r5mn7a
7 Oct 19
Current report (foreign)
6:03am
6-K
7f6ml0k
1 Oct 19
Aslan Pharmaceuticals and Bukwang Pharmaceutical Establish a Joint Venture, Jaguahr Therapeutics, to Develop Novel Immuno-oncology Therapies
6:33am
6-K
dc8d32
28 Aug 19
New Data from Aslan’s Study of Varlitinib In China Accepted As Late-breaking Oral Presentation at 2019 Csco Annual Meeting
6:04am
6-K
k440369a6q765
14 Aug 19
Aslan Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
12:00am
6-K
svgstpd
29 Jul 19
Aslan Pharmaceuticals Names Industry Veteran and Current Board Member Andrew Howden to Additional Role of Chairman
6:11am
6-K
f1ehn86ac qg6
26 Jun 19
Current report (foreign)
6:04am
6-K
tmnr6pp zmb27
26 Jun 19
Current report (foreign)
6:03am
6-K
vlqms9xd
17 Jun 19
Current report (foreign)
9:14am
6-K
w9bywrk
10 Jun 19
Aslan Pharmaceuticals Completes Phase 1 Study for ASLAN004 Targeting Atopic Dermatitis
6:29am
6-K
gga ucg7pw4k6
30 Apr 19
Current report (foreign)
6:04am
6-K
2qfb6 07r
2 Apr 19
Aslan Pharmaceuticals Completes First Part of Single Ascending Dose Study for ASLAN004 Targeting Atopic Dermatitis
6:02am
6-K
dg09ayr
25 Mar 19
Current report (foreign)
6:03am
6-K
uubdtt qdf81s
12 Mar 19
Aslan Pharmaceuticals Signs New Agreement with Biogenetics for Commercialisation of ASLAN003 In South Korea
7:07am
6-K
g8tfhlxs20ky8xq25
27 Feb 19
Aslan Pharmaceuticals to Partner with Biogenetics on Commercialisation of Varlitinib In South Korea
6:02am
6-K
trvw6sq
30 Jan 19
Aslan Pharmaceuticals Announces Strategic Prioritisation of Clinical Development Programs and Corporate Restructuring
6:02am